Hepatitis C treatments are an integral part of the biotech’s product line. Recent approval for a competitor’s comprehensive Hep C drug adds new pressure.
Looking for leads, investment insights, or competitive intelligence?
News about Gilead Sciences
Celgene and Novartis are among the companies accused of thwarting generic drugs.
On hot technologies like CRISPR and CAR-T, China has a leg up, Goldman says.
The new cure could be a boon to poorer nations.
The PrEP drug will be publicly funded in New Zealand for those at high risk for HIV infection.